Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Catapres
2. Catapresan
3. Catapressan
4. Chlophazolin
5. Clofelin
6. Clofenil
7. Clonidine
8. Clonidine Dihydrochloride
9. Clonidine Monohydrobromide
10. Clonidine Monohydrochloride
11. Clopheline
12. Dihydrochloride, Clonidine
13. Dixarit
14. Gemiton
15. Hemiton
16. Hydrochloride, Clonidine
17. Isoglaucon
18. Klofelin
19. Klofenil
20. M 5041t
21. M-5041t
22. M5041t
23. Monohydrobromide, Clonidine
24. Monohydrochloride, Clonidine
25. St 155
26. St-155
27. St155
1. 4205-91-8
2. Clonidine Hcl
3. 2-(2,6-dichloroanilino)-2-imidazoline Hydrochloride
4. Kapvay
5. N-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine Hydrochloride
6. St-155
7. Catapresan
8. Jenloga
9. Clonidine (hydrochloride)
10. Nsc-756699
11. 2-(2,6-dichlorophenylamino)-2-imidazoline Hydrochloride
12. W76i6xxf06
13. Dichloranilino Imidazolin
14. 2-((2,6-dichlorophenyl)imino)imidazolidine Monohydrochloride
15. Benzenamine, 2,6-dichloro-n-2-imidazolidinylidene-, Monohydrochloride
16. Chlophazolin
17. Dispaclonidin
18. Normopresan
19. Atensina
20. Barclyd
21. Capresin
22. Caprysin
23. Catanidin
24. Clofelin
25. Clonilou
26. Clonisin
27. Clonistada
28. Dixarit
29. Edolglau
30. Glausine
31. Haemiton
32. Ipotensium
33. Isoglaucon
34. Katapresan
35. Klophelin
36. Iporel
37. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [cas]
38. Apo-clonidine
39. Clonidil-riker
40. Novo-clonidine
41. Clonid-ophal
42. Nu-clonidine
43. N-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine Hcl
44. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, Monohydrochloride (9ci)
45. 2-[(2,6-dichlorophenyl)amino-2-imidazoline Hydrochloride
46. Bapresan
47. Clonicel
48. Trialox
49. Clonidine Monohydrochloride
50. Smr000466276
51. 205c918
52. Sr-01000075246
53. Einecs 224-121-5
54. Cas-4205-91-8
55. Mfcd00036705
56. N-(2,6-dichlorophenyl)imidazolidin-2-imine;hydrochloride
57. Unii-w76i6xxf06
58. Clonidine-hcl
59. Sr-01000759380
60. Prestwick_73
61. Catapres (tn)
62. 4,5-dihydro-
63. 2-((2,6-dichlorophenyl)amino)-2-imidazoline Hydrochloride
64. 2-imidazoline, 2-(2,6-dichloroanilino)-, Monohydrochloride
65. 2-(2,6-dichlorophenylamino)-2-imidazolin Hydrochlorid [german]
66. Benzenamine, 2,6-dichloro-n-2-imidazolidinylidene-, Hydrochloride
67. Clonidine Hydrochloride [usan:usp:ban:jan]
68. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, Monohydrochloride
69. Clonidinehydrochloride
70. N-(2,6-dichlorophenyl)-
71. Chembl1705
72. Clonidine Hydrochloride,(s)
73. Dsstox_cid_24670
74. Dsstox_rid_80388
75. Dsstox_gsid_44670
76. Schembl40751
77. Mls000758256
78. Mls001424222
79. Clonidine Hydrochloride, Solid
80. 2-(2,6-dichlorophenylamino)-2-imidazolin Hydrochlorid
81. Chebi:3758
82. Dtxsid8044670
83. Hy-b0409a
84. Clonidine Hydrochloride (catapres)
85. Hms1568b18
86. Hms3414h03
87. Hms3678h03
88. Pharmakon1600-01500198
89. Bcp14375
90. Clonidine Hydrochloride [mi]
91. Tox21_301552
92. Tox21_500268
93. Bdbm50020341
94. Ccg-40087
95. Clonidine Hydrochloride (jp17/usp)
96. Clonidine Hydrochloride [jan]
97. N-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine;hydrochloride
98. Nsc756699
99. S2458
100. Clonidine Hydrochloride [usan]
101. Akos005267207
102. Akos024458609
103. Akos028114993
104. Ccg-101051
105. Ccg-212540
106. Ccg-229466
107. Clonidine Hydrochloride [mart.]
108. Clonidine Hydrochloride [vandf]
109. Ks-1253
110. Lp00268
111. Nc00301
112. Nsc 756699
113. Clonidine Hydrochloride [usp-rs]
114. Clonidine Hydrochloride [who-dd]
115. Ncgc00093726-01
116. Ncgc00093726-02
117. Ncgc00180902-01
118. Ncgc00256172-01
119. Ncgc00260953-01
120. Ac-10306
121. Ac-29742
122. Clonidine Hydrochloride, >=98.0% (tlc)
123. Clonidine Hydrochloride [ep Impurity]
124. Clonidine Hydrochloride [orange Book]
125. D1353
126. Eu-0100268
127. Ft-0601096
128. Ft-0665123
129. Sw197681-3
130. Clonidine Hydrochloride [ep Monograph]
131. C 7897
132. Clonidine Hydrochloride [usp Monograph]
133. D00604
134. D81843
135. Clorpres Component Clonidine Hydrochloride
136. A825736
137. Clonidine Hydrochloride 100 Microg/ml In Methanol
138. Combipres Component Clonidine Hydrochloride
139. Clonidine Hydrochloride Component Of Clorpres
140. Q-200880
141. Sr-01000075246-1
142. Sr-01000075246-3
143. Sr-01000759380-5
144. Clonidine Hydrochloride (catapres) [largely Precursor]
145. Clonidine Hydrochloride Component Of Combipres
146. Q27292429
147. 2-[(2,6-dichlorophenyl)imino]imidazolidine Hydrochloride
148. Clonidine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
149. Clonidine Hydrochloride, British Pharmacopoeia (bp) Reference Standard
150. Clonidine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
151. Clonidine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
152. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, Hydrochloride (1:1)
153. N-[2,6-bis(chloranyl)phenyl]-4,5-dihydro-1h-imidazol-2-amine Hydrochloride
Molecular Weight | 266.6 g/mol |
---|---|
Molecular Formula | C9H10Cl3N3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 2 |
Exact Mass | 264.994030 g/mol |
Monoisotopic Mass | 264.994030 g/mol |
Topological Polar Surface Area | 36.4 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 222 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Clonidine hydrochloride |
PubMed Health | Clonidine |
Drug Classes | Analgesic, Anesthetic Adjunct, Antihypertensive, Antimigraine, Cardiovascular Agent, Central Nervous System Agent, Diagnostic Agent, Pheochromocytoma |
Drug Label | Clonidine hydrochloride, USP is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg, and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base.The fo... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release; Injectable; Tablet |
Route | Injection; Oral |
Strength | 0.2mg; 1mg/10ml (0.1mg/ml); 0.3mg; 5mg/10ml (0.5mg/ml); 0.1mg |
Market Status | Prescription |
Company | Exela Pharma Scs; Anchen Pharms; Actavis Elizabeth; Fresenius Kabi Usa; Unichem; Mutual Pharm; Vintage; Alembic Pharms; Hikma Farmaceutica; Luitpold; Sun Pharm Inds; Zydus Pharms Usa; Carlsbad; Mylan; Impax Labs; Dava Pharms |
2 of 4 | |
---|---|
Drug Name | Kapvay |
Drug Label | KAPVAY (clonidine hydrochloride) extended-release is a centrally acting alpha2-adrenergic agonist available as 0.1 mg or 0.2 mg extended-release tablets for oral administration. Each 0.1 mg and 0.2 mg tablet is equivalent to 0.087 mg and 0.174 mg, re... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 0.1mg; 0.2mg |
Market Status | Prescription |
Company | Concordia Pharms |
3 of 4 | |
---|---|
Drug Name | Clonidine hydrochloride |
PubMed Health | Clonidine |
Drug Classes | Analgesic, Anesthetic Adjunct, Antihypertensive, Antimigraine, Cardiovascular Agent, Central Nervous System Agent, Diagnostic Agent, Pheochromocytoma |
Drug Label | Clonidine hydrochloride, USP is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg, and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base.The fo... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release; Injectable; Tablet |
Route | Injection; Oral |
Strength | 0.2mg; 1mg/10ml (0.1mg/ml); 0.3mg; 5mg/10ml (0.5mg/ml); 0.1mg |
Market Status | Prescription |
Company | Exela Pharma Scs; Anchen Pharms; Actavis Elizabeth; Fresenius Kabi Usa; Unichem; Mutual Pharm; Vintage; Alembic Pharms; Hikma Farmaceutica; Luitpold; Sun Pharm Inds; Zydus Pharms Usa; Carlsbad; Mylan; Impax Labs; Dava Pharms |
4 of 4 | |
---|---|
Drug Name | Kapvay |
Drug Label | KAPVAY (clonidine hydrochloride) extended-release is a centrally acting alpha2-adrenergic agonist available as 0.1 mg or 0.2 mg extended-release tablets for oral administration. Each 0.1 mg and 0.2 mg tablet is equivalent to 0.087 mg and 0.174 mg, re... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 0.1mg; 0.2mg |
Market Status | Prescription |
Company | Concordia Pharms |
Sedation
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
FDA has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension for the treatment of ADHD in pediatric patients six years and older.
Lead Product(s): Clonidine
Therapeutic Area: Psychiatry/Psychology Brand Name: Onyda
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2024
Lead Product(s) : Clonidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tris Pharma Gets FDA Approval for ONYDA XR, First Liquid ADHD Medication
Details : FDA has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension for the treatment of ADHD in pediatric patients six years and older.
Brand Name : Onyda
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2024
Details:
JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.
Lead Product(s): Clonidine,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Brand Name: JTA-004
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Lead Product(s) : Clonidine,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioSenic Reacquires Global IP Rights and Provides Update On JTA-004 Development
Details : JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate os...
Brand Name : JTA-004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2023
Details:
Validive® (clonidine hydrochloride) is a novel mucobuccal tablet formulation, indiacted for oropharyngeal cancer. It agonizes the alpha-2 adrenergic receptor on macrophages, decreasing the release of the destructive cytokines that are produced in response to radiotherapy.
Lead Product(s): Clonidine
Therapeutic Area: Immunology Brand Name: Validive
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Lead Product(s) : Clonidine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Validive® (clonidine hydrochloride) is a novel mucobuccal tablet formulation, indiacted for oropharyngeal cancer. It agonizes the alpha-2 adrenergic receptor on macrophages, decreasing the release of the destructive cytokines that are produced in respon...
Brand Name : Validive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 27, 2023
Details:
Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patients.
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Brand Name: Validive
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
Details : Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patie...
Brand Name : Validive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2022
Details:
Validive® (clonidine HCl MBT) is a novel mucobuccal tablet (MBT) formulation of clonidine. A completed double-blind, randomized, placebo-controlled Phase 2 clinical trial showed reduced incidence and duration of SOM and improvement of oral mucositis-related symptoms.
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Brand Name: Validive
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Validive® (clonidine HCl MBT) is a novel mucobuccal tablet (MBT) formulation of clonidine. A completed double-blind, randomized, placebo-controlled Phase 2 clinical trial showed reduced incidence and duration of SOM and improvement of oral mucositis-rel...
Brand Name : Validive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 05, 2022
Details:
The launch of Nexiclon XR, the only once-daily clonidine extended-release tablets is based on Tris's LiquiXR drug delivery technology, which has led to the development of multiple first-in-category products indicated for treatment of hypertension.
Lead Product(s): Clonidine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Nexiclon
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Relea...
Details : The launch of Nexiclon XR, the only once-daily clonidine extended-release tablets is based on Tris's LiquiXR drug delivery technology, which has led to the development of multiple first-in-category products indicated for treatment of hypertension.
Brand Name : Nexiclon
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 03, 2022
Details:
This partnership aligns perfectly with Sabal’s mission to support commercial launch for two products, Nexiclon™ XR and Fibricor®, by helping them deliver their products to physicians and patients who need them.
Lead Product(s): Clonidine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Nexiclon XR
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Athena Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 22, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Athena Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
Details : This partnership aligns perfectly with Sabal’s mission to support commercial launch for two products, Nexiclon™ XR and Fibricor®, by helping them deliver their products to physicians and patients who need them.
Brand Name : Nexiclon XR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 22, 2022
Details:
The trial, which began earlier this year in the US, is evaluating Validive® (clonidine HCl MBT) to prevent the onset of severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients treated with chemoradiotherapy.
Lead Product(s): Clonidine
Therapeutic Area: Oncology Brand Name: Validive
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
Details : The trial, which began earlier this year in the US, is evaluating Validive® (clonidine HCl MBT) to prevent the onset of severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients treated with chemoradiotherapy.
Brand Name : Validive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2021
Details:
The VOICE study evaluates Validive® for the prevention of severe oral mucositis (SOM) in oropharyngeal cancer patients. SOM results from the chemoradiation used to treat oropharyngeal cancer (OPC).
Lead Product(s): Clonidine
Therapeutic Area: Oncology Brand Name: Validive
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
Details : The VOICE study evaluates Validive® for the prevention of severe oral mucositis (SOM) in oropharyngeal cancer patients. SOM results from the chemoradiation used to treat oropharyngeal cancer (OPC).
Brand Name : Validive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 05, 2021
Details:
This analysis provided the rationale for the design of Monopar’s Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.
Lead Product(s): Clonidine
Therapeutic Area: Oncology Brand Name: Validive
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This analysis provided the rationale for the design of Monopar’s Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.
Brand Name : Validive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2021
Regulatory Info :
Registration Country : Sweden
Brand Name : Catapresan
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 150 MICROGRAM / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Catapresan Tts
Dosage Form : Clonidine 2,5Mg 2 Plasters Transdermal Use
Dosage Strength : 2 plasters transd 2.5 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Catapresan
Dosage Form : Clonidine 300Mcg 30 Joined' Oral Use
Dosage Strength : 30 CPR 300 mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Catapresan Tts
Dosage Form : Clonidine 5Mg 2 Plasters Transdermal Use
Dosage Strength : 2 plasters transd 5 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Catapresan
Dosage Form :
Dosage Strength : 30 Cpr 150 Mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Catapresan
Dosage Form : Clonidine 0.15Mg 1Ml 5 Units Parenteral Use
Dosage Strength : 5 VIALS SC IM EV 0.15 mg 1 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Catapresan
Dosage Form : Antic-calc Tablet, drasjert
Dosage Strength : 25 mcg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : Catapres
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 150 MICROGRAM / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Catapres
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 150 MICROGRAM / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Catapres
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 150 MICROGRAM / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Australia
Brand Name : APO-Clonidine
Dosage Form : tablet
Dosage Strength : 100 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : APO-Clonidine
Dosage Form : tablet
Dosage Strength : 100 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Catapres
Dosage Form : tablet
Dosage Strength : 150 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Catapres 100
Dosage Form : tablet
Dosage Strength : 100 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Catapres
Dosage Form : tablet
Dosage Strength : 150 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Catapres 100
Dosage Form : tablet
Dosage Strength : 100 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Clonidine Lupin
Dosage Form : tablet
Dosage Strength : 100 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Clonidine Lupin
Dosage Form : tablet
Dosage Strength : 100 microgram
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Menograine Drops
Dosage Form : DRP
Dosage Strength : 25mg / 0.5ml
Packaging : 5X1mg / 0.5ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Menograine
Dosage Form : TAB
Dosage Strength : 25mcg
Packaging : 100X1mcg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Menograine
Dosage Form : TAB
Dosage Strength : 25mcg
Packaging : 30X1mcg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Dixarit
Dosage Form : TAB
Dosage Strength : 0.025mg
Packaging : 100X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?